Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

Slides:

Advertisements

Similar presentations

JHSGR 16 th April 2011 Dr Lee Man Kit Derek.  The value of PET in staging adenocarcinoma (e.g. colorectal cancer) is well established Tomoharu T. et.

Advertisements

© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.

© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.

Dual-time point 18F-FDG PET/CT scan: is it always working?

Thorax / Lung Basic Science Conference 12/21/2005 J.R. Nitzkorski.

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

Acinic Cell Carcinoma of the Parotid Gland Metastatic to the Epidermis of the Back Pilcher R. Davidson MJC. Department of Oral and Maxillofacial Surgery,

WORK UPS. Ultrasound method of choice for the differentiation of cysts from solid masses and for guidance in interventional procedures. Benign: – solid.

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

Cancer Basics EQ: What does cancer have to do with the cell cycle?

Supraclavicular metastasis from urothelial bladder carcinoma: A case report S. Farmahan, T. Mirza, P. Ameerally Oral Maxillofacial Department, Northampton.

Metastases to the breast. 49-year-old woman Palpable lump in the left breast.

CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.

Brain imaging prior to lung cancer resection

CT and PET imaging in non-small cell lung cancer

Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer Respiration 2015;90: DOI: /

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Keith E. Kelly, MD and William H. Culbertson, MD

Basile Pache, Antonia Digklia*, Nicolas Demartines, Maurice Matter.

Squamous cell carcinoma

Brain imaging prior to lung cancer resection

A 55 year-old with lung cancer and leg numbness

Two lesions are seen within the lateral segment of the left lobe of the liver (yellow arrows). They appear mildly hyperintense on T2 images and mildly.

Michael Lin, Jenn Hian Koo, David Abi–Hanna

How I treat extramedullary myeloma

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

New Patient Journeys in Non-small cell lung cancer

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD

A, baseline and 4-week PET scan from patient 2 (MET c

Detection of extrathoracic metastases by positron emission tomography in lung cancer Walter Weder, MD, Ralph A Schmid, MD, Helke Bruchhaus, MD, Sven Hillinger,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

Clinical responses in patients.

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Fig F-FGln shows uptake in human gliomas undergoing progression.

Multiple (type 3) cyst-related primary lung malignancies presenting as cystic airspaces with asymmetrical or circumferential wall thickening. a, b) A 52-year-old.

Volume 10, Pages 1-4 (December 2016)

Pulmonary nodules discovered on CT scan of the chest

The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;

Combining Immunotherapy and Chemotherapy in NSCLC

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Off-midline non-contrast-enhanced sagittal T1-weighted MR image (600/12/1) in a 48-year-old woman with breast cancer who presented with headache and fatigue.

General strategies of Cancer Treatment and evaluation of Response

Frequent alterations identified and potential actionability.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

Gamma camera images at 72 h of patient with T3N0M0 squamous cell cancer of the tongue base (patient 14). Gamma camera images at 72 h of patient with T3N0M0.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Location of the ER mutations and frequencies per cohort.

A) Chest CT showing a lobulated necrotic mass in left hilar region with foci of calcifications and spiculated margins at the time of diagnosis. b) PET-CT.

Frequent coamplification of RTKs in MET-amplified EGC

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Serial CT scan images from patient with a partial response.

Survival, subsequent therapies, and response.

Detection of E-cadherin fragments in human prostate cancer metastases.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Figure 12a Pitfalls in N staging at CT and PET

Patient 8 is a 55-year-old woman with multiple liver metastases from renal cell carcinoma who underwent liver wedge resection and intraoperative chemotherapy.

Presentation transcript:

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Baseline imaging refers to images about 2 months before immunotherapy. Preimmunotherapy imaging refers to imaging immediately before immunotherapy. A, Case #1: Patient with bladder carcinoma. Tumor showed gradual progression over several months before atezolizumab. Restaging 1.9 months after atezolizumab showed a 258% increase in tumor size compared with preimmunotherapy accompanied by a dramatic increase in PET FDG avidity and new liver masses. Follow-up imaging 2.8 months after the initiation of atezolizumab confirmed the progression (imaging not shown), and the patient died soon afterwards. B, Case #2: patient with triple-negative breast cancer. While receiving local therapy against brain metastases, left lung metastasis was overall stable. However, 1.5 months after the initiation of pembrolizumab, a CT scan revealed a 55% increase of the left lung mass as well as new chest wall masses and lymphadenopathy. C, Case #3: patient with endometrial stromal sarcoma. Patient had shown increase in tumor size and CA125 (11 to 33 U/mL) over 6 months. On 1.5 months of nivolumab, CT imaging demonstrated rapid progression of liver metastases and new bulky abdominal masses (overall 242% increase from preimmunotherapy imaging; top). CA125 also increased from 33 to 1040 (U/mL; bottom). D, Case #4: patient with adenocarcinoma of lung. Patient had gradual progression on Abraxane. Soon after starting pembrolizumab, patient noted severe fatigue/malaise, which prompted the physician to obtain repeat CT imaging. The scan showed rapid progression of known lung metastases (135% increase from preimmunotherapy). E, Case #5: patient with adenocarcinoma of lung. After first-line chemotherapy, imaging detected new lung disease. Patient was then started on pembrolizumab. However, patient noticed rapidly worsening shortness of breath and severe generalized fatigue. Although CT of the chest showed stable disease, patient was taken off therapy for clinical progression about 1.5 months after the initiation of pembrolizumab. Subsequent MRI of the brain showed multiple new brain metastases. F, Case #6, patient with squamous cell carcinoma of the hypopharynx was treated with an OX40 agonist (third-line therapy). Within 1.4 months, patient was taken off study due to progressive altered mental status secondary to worsening hyponatremia attributed to tumor-associated SIADH. Imaging at the time was stable. The patient died 3 months later. Shumei Kato et al. Clin Cancer Res 2017;23:4242-4250 ©2017 by American Association for Cancer Research